Gossamer Bio, Inc. (GOSS)

Gossamer Bio's stock has experienced significant upward movement in the past six months. Key events impacting the stock price include the Q1 2025 earnings release, the Q2 2025 earnings release, analyst upgrades in August 2025, an option agreement with Respira Therapeutics on September 25, 2025, presentations at the European Respiratory Society (ERS) Congress 2025 on September 22, 2025, and positive analyst sentiment as of October 2025.

Demand for Gossamer Bio's products and services is not subject to typical seasonal fluctuations. Demand for such therapies is driven by disease prevalence, medical need, and the efficacy and approval of its drug candidates, rather than seasonal patterns.

Gossamer Bio, Inc. (GOSS) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for immunology, inflammation, and oncology. Their lead product candidate, seralutinib (GB002), is in Phase 3 clinical trials for pulmonary arterial hypertension (PAH) and is being evaluated for pulmonary hypertension with interstitial lung disease (PH-ILD). The company has license agreements with Pulmokine, Inc. for the development and commercialization of GB002 and related compounds.

Gossamer Bio, Inc. is headquartered in San Diego, California, United States. Its clinical operations, particularly for the Phase 3 PROCERA study, are global, with teams working across the globe to enroll patients.

Gossamer Bio's brand reputation in the past year appears to be largely positive within the investment and medical communities, primarily driven by the potential of its lead drug candidate, seralutinib. The company has received "Strong Buy" ratings from analysts. The successful enrollment of its pivotal Phase 3 PROCERA study and plans for the SERENATA Phase 3 PH-ILD trial contribute to this positive perception.

Gossamer Bio, Inc. has a diverse ownership structure, with institutional shareholders holding a significant portion, insiders owning around 9.97% to 15.17%, and retail investors holding approximately 6.88% to 69.02%. Major institutional owners include Octagon Capital Advisors LP, NEA Management Company, LLC, Omega Fund V LP, BlackRock, Inc., Vanguard Group Inc, Arch Venture Management LLC, Fmr LLC, Acadian Asset Management LLC, 683 Capital Management LLC, and Samsara Biocapital LLC. Faheem Hasnain, the CEO, holds a notable individual stake.